Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a prevalent autoimmune disease with complex pathogenesis.
• Epigenetic modifications, particularly involving microRNAs (miRNAs), play a role in RA development and progression.
• Conventional disease-modifying antirheumatic drugs (DMARDs) are not universally effective, necessitating exploration of alternative therapeutic targets and biomarkers.

Purpose of the Study:

• To quantify plasma miRNA expression levels in RA patients undergoing olokizumab therapy.
• To identify potential prognostic biomarkers for predicting therapeutic response to olokizumab.
• To correlate miRNA expression changes with treatment efficacy in RA.

Main Methods:

• Plasma samples from 103 RA patients were analyzed before and during 24 weeks of olokizumab treatment.
• Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression of 9 specific miRNAs.
• Statistical analyses, including ROC curve, univariate, and multivariate regression, were performed on responders and non-responders.

Main Results:

• Significant alterations in miRNA expression were observed in most miRNAs during olokizumab therapy.
• ROC curve and regression analyses identified miR-26b, miR-29, miR-451, and miR-522 as significantly associated with olokizumab efficacy.
• These specific miRNAs demonstrated potential as indicators of treatment response.

Conclusions:

• Plasma miRNAs, particularly miR-26b, miR-29, miR-451, and miR-522, may serve as valuable prognostic biomarkers for olokizumab therapy in RA patients.
• Monitoring these miRNAs could aid in personalizing RA treatment strategies.
• Further research is warranted to validate these findings and explore their clinical utility.